%0 Journal Article
%T Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer
%A Barbara Dockhorn-Dworniczak
%A Beatriz Bellosillo
%A Christiana Rossenbach
%A Clara Montagut
%A Claudia M. Luna-Aguirre
%A Federico Rojo
%A Francesca Castiglione
%A Hendrikus J. Dubbink
%A Hilla Tabibian-Keissar
%A Hugo A. Barrera-Salda£¿a
%A Iv¨¢n Prieto-Potin
%A Jean-Christophe Sabourin
%A Jos¨¦ C. Machado
%A Jos¨¦ L. Costa
%A Karl-Friedrich B¨¹rrig
%A Linea Melchior
%A Livia Ronchetti
%A Lotte Douglas-Berger
%A Matthew Evans
%A Matthew Smith
%A Michael Bennett
%A Mohammed Alorini
%A Rinat Yacobi
%A Simonetta Buglioni
%A Ulrike Cooper
%A Veronica Pennati
%A Werner Reiltin
%J The Journal of Molecular Diagnostics
%D 2018
%R 10.1016/j.jmoldx.2018.05.008
%X Treatment of colorectal cancer (CRC) with monoclonal antibodies against epidermal
growth factor receptor requires the assessment of the mutational status of exons 2,
3, and 4 of the NRAS and KRAS oncogenes. Moreover, the mutational status of exon 15
of the BRAF oncogene is a marker of poor prognosis in CRC. The Idylla NRAS-BRAF Mutation
Test is a reliable, simple (<2 minutes hands-on time), and quick (<2 hours turnaround
time) sample-to-result solution, enabling the detection of clinically relevant mutations
in NRAS (18 mutations) and BRAF (5 mutations).
%U https://jmd.amjpathol.org/article/S1525-1578(18)30095-3/fulltext